Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia

APMIS

Volumn 119, Issue 1, 2011, Pages 76-84

  Li, Xiaoqing ^a   Li, Juan ^a   Du, Wen ^a   Zhang, Jiahua ^a   Liu, Wei ^a   Chen, Xiangjun ^a   Li, Hongrui ^a   Huang, Shiang ^a   Li, Xin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute myeloid leukemia; Cytogenetics; Immunophenotyping; Prognosis; Risk stratification

Indexed keywords

CD11B ANTIGEN; CD123 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD64 ANTIGEN; CD7 ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; GLYCOPHORIN A; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AGING; ANTIGEN EXPRESSION; ARTICLE; CHILD; CONTROLLED STUDY; CYTOGENETICS; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DNA NUCLEOTIDYLEXOTRANSFERASE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 78650100291     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02694.x     Document Type: Article

References (55)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
2. Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66:181-93.
3. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009:385-95.
4. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
5. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007;12:341-55.
6. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598-605.
7. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006:169-77.
8. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-36.
9. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35.
10. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61-9.
11. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-87.
12. Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 2006;47:1245-52.
13. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002;99:3517-23.
14. Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008;32:1221-7.
15. Krykowski E, Polkowska-Kulesza E, Robak T, Matusewicz W, Urba-ska-Rys H, Holub A. Analysis of prognostic factors in acute leukemias in adults. Haematol Blood Transfus 1987;30:369-72.
16. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008;111:3183-9.
17. Ryningen A, Bruserud Ø. Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects. Curr Pharm Biotechnol 2007;8:401-11.
18. Schabath R, Ratei R, Ludwig WD. The prognostic significance of antigen expression in leukaemia. Best Pract Res Clin Haematol 2003;16:613-28.
19. Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 2006;20:71-82.
20. Béné MC, Bernier M, Castoldi G, Faure GC, Knapp W, Ludwig WD, et al. Impact of immunophenotyping on management of acute leukemias. Haematologica 1999;84:1024-34.
21. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006;24:3686-92.
22. Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Ceresoli E, Lo Coco F, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2009;21:582-8.
23. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009;131:16-26.
24. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
25. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, et al. Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008: 109-47.
26. Li X, Du W, Liu W, Li X, Li H, Huang SA. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS 2010;118:353-9.
27. Callea V, Morabito F, Martino B, Stelitano C, Oliva B, Nobile F. Diagnostic and prognostic relevance of the immunophenotype in acute myelocytic leukemia. Tumori 1991;77:28-31.
28. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995;84:60-8.
29. Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 2004;28:43-8.
30. Webber BA, Cushing MM, Li S. Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. Int J Clin Exp Pathol 2008;1:124-33.
31. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom 2003;53:11-19.
32. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994;8:388-94.
33. Miwa H, Nakase K, Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk Lymphoma 1996;21:239-44.
34. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G, et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998;12:1056-63.
35. Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001;115:612-15.
36. Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003;17:515-27.
37. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 2005;79:39-41.
38. Chang H, Yeung J, Brandwein J, Yi QL. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res 2007;31:157-62.
39. Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S, et al. Clinical importance of CD7 expression in acute myelocytic leukemia: the Japan Cooperative Group of Leukemia/Lymphoma. Blood 1993;81:2399-405.
40. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986;68:1232-41.
41. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990;8:423-30.
42. Solary E, Casasnovas RO, Campos L, Béné MC, Faure G, Maingon P, et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival: Groupe d'Etude Immunologique des Leucémies (GEIL). Leukemia 1992;6:393-9.
43. Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer 2008;112:572-80.
44. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem cell glycoprotein CD34 (My-10). Br J Haematol 1990;76:340-7.
45. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi GL. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukaemia. Leuk Lymphoma 1994;13:S81-5.
46. Lauria F, Raspadori D, Ventura MA, Rondelli D, Testoni N, Tosi P, et al. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells 1995;13:428-34.
47. Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, De Vivo A, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997;21:603-7.
48. Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. Leukemia 1993;7:1142-50.
49. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia: Australian Leukaemia Study Group. Blood 1994;84:1220-5.
50. Tucker J, Dorey E, Gregory WM, Simpson AP, Amess JA, Lister TA, et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. Hematol Oncol 1990;8:47-58.
51. Vidriales MB, Orfao A, López-Berges MC, González M, López-Macedo A, Ciudad J, et al. Prognostic value of S-phase cells in AML patients. Br J Haematol 1995;89:342-8.
52. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS, et al. Acute myeloid leukaemia expressing the leucocyte integrin CD11b - a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Br J Haematol 1998;100:265-72.
53. San Miguel JF, Ojeda E, Gonzalez M, Orfao A, Cañizo MC, Sanchez J, et al. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia 1989;3:108-11.
54. Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA. Expression of a 150-kD cell surface antigen identified by a monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukemia. Leuk Res 1988;12:923-8.
55. Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77:2242-50.